Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA.
Leukemia. 2011 Feb;25(2):211-7. doi: 10.1038/leu.2010.248. Epub 2010 Nov 16.
Under normal conditions, the great majority of hematopoietic stem/progenitors cells (HSPCs) reside in the bone marrow. The number of HSPCs in the circulation can be markedly increased in response to a number of stimuli, including hematopoietic growth factors, myeloablative agents and environmental stresses such as infection. The ability to 'mobilize' HSPCs from the bone marrow to the blood has been exploited clinically to obtain HSPCs for stem cell transplantation and, more recently, to stimulate therapeutic angiogenesis at sites of tissue ischemia. Moreover, there is recent interest in the use of mobilizing agents to sensitize leukemia and other hematopoietic malignancies to cytotoxic agents. Key to optimizing clinical mobilizing regimens is an understanding of the fundamental mechanisms of HSPC mobilization. In this review, we discuss recent advances in our understanding of the mechanisms by which granulocyte colony-stimulating factor (G-CSF), the prototypical mobilizing agent, induces HSPC mobilization.
在正常情况下,绝大多数造血干/祖细胞(HSPCs)存在于骨髓中。在多种刺激物的作用下,包括造血生长因子、骨髓清除剂和感染等环境应激,循环中的 HSPC 数量可以显著增加。从骨髓中“动员”HSPC 到血液中的能力已在临床上得到利用,以获取用于干细胞移植的 HSPCs,并且最近还用于刺激组织缺血部位的治疗性血管生成。此外,最近人们对使用动员剂使白血病和其他造血恶性肿瘤对细胞毒性药物敏感产生了兴趣。优化临床动员方案的关键是了解 HSPC 动员的基本机制。在这篇综述中,我们讨论了对粒细胞集落刺激因子(G-CSF)诱导 HSPC 动员的机制的最新理解的进展,G-CSF 是典型的动员剂。